Celiac Disease

Immunology·MeSH: Celiac Disease

17 drugs in development·13 companies·11 clinical trials

Drug Pipeline by Phase

Phase 3(6)

Drug	Company
imu-856	IMMUNIC, INC. (IMUX)
tak-062	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-062	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-101	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-101	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tev-53408	Teva Pharmaceutical Industries Limited (TEVA)

Phase 2(6)

Drug	Company
fb-102	Forte Biosciences, Inc. (FBRX)
fb102	Forte Biosciences, Inc. (FBRX)
ordesekimab	PROVENTION BIO, INC. (PBI)
prv-015	PROVENTION BIO, INC. (PBI)
prv-015	Sanofi (SNY)
TEV-53408	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 1(2)

Drug	Company
amt-126	Applied Molecular Transport Inc. (AMTI)
ANB033	ANAPTYSBIO, INC (ANAB)

Preclinical(2)

Drug	Company
eq302	Equillium, Inc. (EQ)
tac-celiac	SQZ Biotechnologies Co (SQZB)

Early Phase 1(1)

Drug	Company
VTP-1000	Barinthus Biotherapeutics plc. (BRNS)

BioSniper tracks 17 drugs in development for Celiac Disease across 13 companies.

There are 11 clinical trials targeting Celiac Disease tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.